SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG

SG&A Efficiency: A Tale of Two Biotech Giants

In the dynamic world of biotechnology, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Gilead, a stalwart in the industry, consistently reported SG&A expenses that were approximately 70 times higher than those of the innovative CRISPR Therapeutics. Over the decade, Gilead's expenses grew by about 104%, peaking in 2023, while CRISPR's expenses surged by over 1,300%, reflecting its rapid expansion and investment in groundbreaking gene-editing technologies. This stark contrast highlights the differing scales and strategies of these companies. Gilead's stable yet substantial expenses underscore its established market presence, whereas CRISPR's rising costs signal its aggressive growth trajectory. As the biotech landscape evolves, these insights offer a glimpse into the financial strategies shaping the future of healthcare.